James Gail Christensen

This inventor holds 24 USPTO granted patents and 21 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Cancer Therapies. Top assignees: Mirati Therapeutics, Inc., Array Biopharma Inc., Pfizer Corporation. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James Gail Christensen. Retrieved from https://idiyas.com/inventor/james-gail-christensen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 21)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 16)

EPO Patents = 8 (Patent Applications = 29)

Average Co-Inventor Count = 5.7

ph-index = 6

Forward Citations = 106(Granted Patents)

Company Filing History:

23 out of 44

Mirati Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

KRas G12D Inhibitors

KRas G12C Inhibitors

PRC2 Inhibitors

Combination Therapies

Adagrasib

mTOR Inhibitors

Palbociclib

LSD1 Inhibitors

Imidazo[1,2-c]pyrimidines

Cancer Treatment

PRMT5 Inhibitors

Cell Growth

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747253 - KRas G12D inhibitors (2026-09-29),

2. 12630566 - KRas G12D inhibitors (2026-05-19),

3. 12527795 - Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith (2026-01-20),

4. 12485122 - Combination of palbociclib and adagrasib for lung cancer (2025-12-02),

5. 12377101 - Combination therapies (2025-08-05),

6. 12371435 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2025-07-29),

7. 12336995 - Combination therapies (2025-06-24),

8. 12208099 - Combination therapies (2025-01-28),

9. 12171765 - Combination therapies using PRMT5 inhibitors for the treatment of cancer (2024-12-24),

10. 12128048 - Combination therapies using PRMT5 inhibitors for the treatment of cancer (2024-10-29),

11. 11964989 - KRas G12D inhibitors (2024-04-23),

12. 11890285 - Combination therapies (2024-02-06),

13. 11548888 - KRas G12C inhibitors (2023-01-10),

14. 11485738 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2022-11-01),

15. 11453683 - KRas G12D inhibitors (2022-09-27),

Title: James Gail Christensen: Pioneering Inventor Revolutionizing Cancer Treatment

Introduction: James Gail Christensen is a pioneering inventor based in San Diego, California, whose passion for innovation and dedication to creating impactful solutions have solidified his reputation as a key figure in the field of biomedical inventions.

Latest Patents: With an impressive total of 14 patents to his name, James Gail Christensen's most recent groundbreaking inventions include KRas G12D inhibitors - compounds designed to inhibit the activity of KRas G12D, particularly in the treatment of cancer. His latest patent also involves combination therapies for treating KRas G12C cancers, showcasing his commitment to advancing cancer treatment methodologies.

Career Highlights: Throughout his illustrious career, James Gail Christensen has made significant contributions to the field of biopharmaceuticals while working with reputable companies such as Mirati Therapeutics, Inc. and Array Biopharma Inc. His innovative work in developing novel cancer treatment methods has garnered recognition and praise from peers and industry experts alike.

Collaborations: James Gail Christensen has collaborated closely with accomplished individuals in the field, including coworkers Matthew Arnold Marx and John Peter Fischer. Together, they have worked towards revolutionizing cancer treatment through the development of cutting-edge therapies and solutions.

Conclusion: James Gail Christensen's relentless drive for innovation and his transformative contributions to the field of biomedical inventions exemplify his status as a pioneering inventor. His innovative patents and collaborations underscore his commitment to creating impactful solutions that have the potential to revolutionize cancer treatment methodologies and improve patient outcomes globally.

Profile summary based on public USPTO records.